Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults
Improves skin texture
A branded semaglutide product is FDA-approved and dispensed through retail pharmacies
SURMOUNT-5 data (2025) shows tirzepatide achieves approximately 47% greater weight loss than semaglutide overall, suggesting stronger average appetite control
US$ 28.68
US$ 26.37
US$ 28.89
US$ 20.12
US$ 20.71
US$ 25.83
US$ 27.02
US$ 26.67
US$ 24.02
US$ 29.69
